Intraparenchymal rAAV1 - (mi)RNA HTT ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 8 | Huntington disease | 1 |
8. Huntington disease
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04885114 (ClinicalTrials.gov) | July 30, 2021 | 2/3/2021 | Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease | A Phase 1B, Open-label, Randomized, Controlled, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Biological Effects of VY-HTT01 Administered Via Intraparenchymal Infusion of the Putamen and Thalamus in Adults With Huntington's Disease | Huntington Disease | Genetic: Intraparenchymal rAAV1 - (mi)RNA HTT | Voyager Therapeutics | NULL | Withdrawn | 18 Years | N/A | All | 0 | Phase 1 | NULL |